Read the February issue

Including articles on rare diseases, FDA drug approvals and biopharma deals in 2019, targeting mRNA processing in cancer and predictive models of drug-induced liver injury.

Latest Reviews

  • Review Article |

    Naturally occurring cationic host defence peptides, also known as antimicrobial peptides, can control infections by their direct microbicidal properties and by modulating the host’s immune responses. In addition, certain cationic host defence peptides can resolve harmful inflammation. Here, Mookherjee et al. assess the emerging potential to therapeutically harness these peptides to treat infectious diseases, chronic inflammatory disorders and wound healing, highlighting current preclinical studies and clinical trials.

    • Neeloffer Mookherjee
    • , Marilyn A. Anderson
    • , Henk P. Haagsman
    •  & Donald J. Davidson
  • Review Article |

    Current seasonal influenza vaccines lack efficacy against drifted or pandemic virus strains, and the development of novel vaccines that elicit broader immunity represents a public health priority. Here, Nabel and colleagues discuss approaches to improve vaccine efficacy which harness new insights from influenza antigen structure and human immunity, highlighting major targets, vaccines in development and ongoing challenges.

    • Chih-Jen Wei
    • , Michelle C. Crank
    • , John Shiver
    • , Barney S. Graham
    • , John R. Mascola
    •  & Gary J. Nabel
  • Review Article |

    Neutrophils play diverse roles in various disease processes, including infection, pulmonary diseases, autoimmune and inflammatory disorders, cardiovascular diseases and cancer. Here, Mócsai and colleagues provide an overview of the biological and pathological functions of neutrophils, assessing emerging strategies to therapeutically target neutrophils and agents currently under investigation.

    • Tamás Németh
    • , Markus Sperandio
    •  & Attila Mócsai
  • Review Article |

    Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. This Review discusses new approaches to activate NK cells, increase their proliferation in vivo and increase their capacity to recognize tumour cells.

    • Noriko Shimasaki
    • , Amit Jain
    •  & Dario Campana
  • Review Article |

    The use of allogeneic chimeric antigen receptor T cells from donors has many potential advantages over autologous approaches, such as immediate availability, standardization and the possibility of redosing or combination. This Review analyses the different sources of T cells and technological approaches to produce optimal allogeneic chimeric antigen receptor T cells with limited potential for graft-versus-host disease and increased persistence.

    • S. Depil
    • , P. Duchateau
    • , S. A. Grupp
    • , G. Mufti
    •  & L. Poirot
  • Perspective |

    Oral delivery of peptide therapeutics could have benefits for treatment adherence, but it faces barriers related to the structural organization and physiological function of the gastrointestinal tract. This article highlights strategies to overcome these barriers and discusses experience with oral peptides that have reached clinical trials, including the recent landmark approval of an oral formulation of semaglutide for the treatment of type 2 diabetes.

    • Daniel J. Drucker

News & Comment

Nature events Directory